Clinical Trials
4 trialsNCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06369480 2024-04-17
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Rigshospitalet, Denmark
Unknown
NCT04523402 2020-08-21
Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT04506281 2020-08-10
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2 Unknown